Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

Epidiolex (Cannabidiol): A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

(2019) Jeffrey W. Chen et al.   ANNALS OF PHARMACOTHERAPY

Concatenated γ-aminobutyric acid type A receptors revisited: Finding order in chaos

(2019) Vivian Wan Yu Liao et al.   JOURNAL OF GENERAL PHYSIOLOGY

The Pharmacokinetics and the Pharmacodynamics of Cannabinoids

(2018) C.J. Lucas et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

(2018) Orrin Devinsky et al.   NEUROLOGY

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience

(2018) Kerrie-Anne Chen et al.   MEDICAL JOURNAL OF AUSTRALIA

Interactions between cannabidiol and commonly used antiepileptic drugs

(2017) Tyler E. Gaston et al.   EPILEPSIA

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors

(2017) T. Bakas et al.   PHARMACOLOGICAL RESEARCH

Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome

(2017) Joshua S. Kaplan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Screening of conventional anticonvulsants in a genetic mouse model of epilepsy

(2017) Nicole A. Hawkins et al.   Annals of Clinical and Translational Neurology

Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol

(2016) Reesha R. Patel et al.   BRAIN

Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes

(2016) Xiu-Yu Shi et al.   BRAIN & DEVELOPMENT

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex

(2016) Evan J. Hess et al.   EPILEPSIA

Mortality in Dravet syndrome: A review

(2016) Sharon Shmuely et al.   EPILEPSY & BEHAVIOR

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

(2016) Orrin Devinsky et al.   LANCET NEUROLOGY

Pharmacotherapy for Dravet Syndrome

(2016) Adam Wallace et al.   PEDIATRIC DRUGS

Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq

(2016) Nicole A. Hawkins et al.   PLoS Genetics

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

(2015) Alexandra L. Geffrey et al.   EPILEPSIA

The Direct Actions of GABA, 2’-Methoxy-6-Methylflavone and General Anaesthetics at β3γ2L GABAA Receptors: Evidence for Receptors with Different Subunit Stoichiometries

(2015) Han Chow Chua et al.   PLoS One

Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability

(2014) Fabio Arturo Iannotti et al.   ACS Chemical Neuroscience

Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA–Receptor Complexes

(2014) Henrik Sindal Jensen et al.   PLoS One

Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome

(2014) C. Tai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19

(2013) Rongrong Jiang et al.   Drug Metabolism and Pharmacokinetics

Influence of CYP2C19 Polymorphism and Concomitant Antiepileptic Drugs on Serum Clobazam and N-Desmethyl Clobazam Concentrations in Patients With Epilepsy

(2013) Yoshiaki Yamamoto et al.   THERAPEUTIC DRUG MONITORING

Pharmacokinetic Drug Interactions Between Clobazam and Drugs Metabolized by Cytochrome P450 Isoenzymes

(2012) Mark Walzer et al.   PHARMACOTHERAPY

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures

(2012) Nicholas A. Jones et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam

(2011) Raman Sankar   CNS DRUGS

Dravet syndrome: The long-term outcome

(2011) Pierre Genton et al.   EPILEPSIA

The core Dravet syndrome phenotype

(2011) Charlotte Dravet   EPILEPSIA

The genetics of Dravet syndrome

(2011) Carla Marini et al.   EPILEPSIA

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

(2011) Rongrong Jiang et al.   LIFE SCIENCES

Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety

(2011) Satoshi Yamaori et al.   LIFE SCIENCES

Molecular basis of severe myoclonic epilepsy in infancy

(2009) Kazuhiro Yamakawa   BRAIN & DEVELOPMENT

Impact ofCYP2C19polymorphisms on the efficacy of clobazam therapy

(2008) Takayuki Seo et al.   PHARMACOGENOMICS

The orphan receptor GPR55 is a novel cannabinoid receptor

(2007) E Ryberg et al.   BRITISH JOURNAL OF PHARMACOLOGY